CoChat
Sign Up
Cited by 112Autism Spectrum Disorder ResearchNeuroendocrine regulation and behaviorGenetics and Neurodevelopmental Disorders

The DOI matches its Crossref record; 36 of the 39 references it cites were found in a registry or an index.

Low-dose naltrexone effects on plasma chemistries and clinical symptoms in autism: a double-blind, placebo-controlled study

Bouvard, Manuel P., Leboyer, Marion, Launay, Jean-Marie, Recasens, Christophe, Plumet, Marie-Hélène, Waller-Perotte, Delphine, Tabuteau, François, Bondoux, Dominique, Dugas, Michel, Lensing, Patrick, Panksepp, Jaak·1995·Psychiatry Research
DOI 10.1016/0165-1781(95)02601-r
Open this paper in CoChat — free account

Abstract

The effect of month-long naltrexone (NTX) treatment at a daily oral dose of 0.5 mg/kg/day was contrasted with placebo (PLC) in a double-blind study with conjoint clinical and biochemical evaluations of therapeutic effects. Modest clinical benefits were achieved with both PLC and NTX, with marginally better overall results following NTX, and degree of improvement appeared to be related to plasma chemical profiles. Massively elevated levels of beta-endorphin were observed in all children with assays using C-terminal antibody but not with an N-terminal antibody assay. In addition, 70% of the children exhibited abnormally low levels of adrenocorticotropic hormone, and smaller subsets exhibited elevated norepinephrine (60%), arginine-vasopressin (50%), and serotonin (20%). The best clinical responders exhibited the clearest normalization of the elevated plasma chemistries, especially in C-terminal-beta-endorphin and serotonin. There was some evidence of therapeutic carry-over effects in both clinical and biochemical measures in those children who received NTX before PLC. The results suggest that NTX only benefits a subgroup of autistic children, who may be identified by the presence of certain plasma abnormalities. These results suggest a possible linkage between abnormal plasma chemistries, especially those related to the pro-opiomelanocortin system, and autistic symptoms.

Overview

Integrity signals

Registry

Crossref · 10.1016/0165-1781(95)02601-r

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Observational studies in patients with autism have shown that administration of an opioid antagonist could decrease self-injurious behavior, stereotypies, hyperactivity, and withdrawal, while increasing verbal production, social communication, proximity seeking, and eye contact.

    “Observational studies in patients with autism have shown that administration of an opioid antagonist could decrease self-injurious behavior, stereotypies, hyperactivity, and withdrawal, although increasing verbal production, social communication, proximity seeking, and eye contact (47–50).”

    From Oxytocin under opioid antagonism leads to supralinear enhancement of social attention (2017) · cites this paper as [47]

Citations

Cites

Flagged first, then by citations

3 of the 39 references couldn’t be matched to a known paper.

Research works printed but not linked: 2

  1. Leboyer, 1990, The opioid excess hypothesis of autism: a double-blind study of naltrexone, Brain Dysfunction, 3, 285
  2. Lensing, 1992, Naltrexone open-trial with a five year old boy: a social rebound reaction, Acta Paedopsychiatr, 55, 169

Cited by

Sorted by citations

Related

Metadata

Authors
Bouvard, M. P., Leboyer, M., Launay, J.-M., Recasens, C., Plumet, M.-H., Waller-Perotte, D., Tabuteau, F., Bondoux, D., Dugas, M., Lensing, P., & Panksepp, J.
Affiliations
  • Hôpital Robert-Debré (FR)
  • Pitié-Salpêtrière Hospital (FR)
  • Hôpital Saint-Louis (FR)
  • Bowling Green State University (US)
Corresponding author
Panksepp, Jaak
ORCID
Venue
Psychiatry Research
Publisher
Elsevier BV
Published
1995-10
Volume
58
Issue
3
Pages
191-201
ISSN
0165-1781 (ISSN-L)
DOI
10.1016/0165-1781(95)02601-r
OpenAlex
W1963985457
Cited by
112
References
39
Citations by year
2026: 2 · 2025: 1 · 2024: 2 · 2023: 2 · 2022: 3 · 2021: 3 · 2020: 4 · 2019: 3 · 2018: 5 · 2017: 3 · 2016: 7 · 2015: 1 · 2014: 3 · 2013: 5 · 2012: 7
FWCI
1.71
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Psychiatry Research (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Neuroendocrine regulation and behavior
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
Keywords
naltrexone, autism spectrum disorder, beta-endorphin, ACTH, norepinephrine, vasopressin, serotonin, plasma chemistry, placebo response
MeSH terms
Adolescent, Autistic Disorder, beta-Endorphin, Child, Child, Preschool, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Female, Humans, Male, Naltrexone, Narcotic Antagonists, Personality Assessment, Neurotransmitter Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review